Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 378 participants.

Also called NCT03145675

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 378 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03145675
Other papers using this trial's data
  • Trough anticoagulant levels of high-dose versus standard-dose intravenous enoxaparin in patients undergoing trans-radial coronary angiography alone BMC cardiovascular disorders, 2026-02-19 DOI, PubMed 41714948, PMC13019850 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03145675. Randomized; no masking; primary purpose treatment. Start 2017-05-12 (actual); primary completion 2022-04-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)
Acronym
OPTIENOX-PCI
Intervention (Drug)
Enoxaparin (Staged-dose PCI Group)
Intervention (Drug)
Enoxaparin (Single-dose PCI Group)
Intervention (Drug)
Enoxaparin (High-dose Group)
Intervention (Drug)
Enoxaparin (Standard-dose Group)
Lead sponsor
Peking Union Medical College Hospital (class: other)

Record details

Record id
cardio:ct-nct03145675
Content hash
5d17257010114f1f62174914ebc9ecdb8db467865af7723a5d61e24ceff3b26b